Developer docs
API playgroundTry for free, no card

Search company profiles

Vaxcyte

Full company profile

uuid0000yl6

Namestring
Vaxcyte
Legal namestring
Vaxcyte, Inc.
Websiteurl
vaxcyte.com
Company typeenum
Public
Founded yearint
2013
Descriptiontext

Vaxcyte, Inc. (NASDAQ: PCVX) is a clinical-stage vaccine innovation company founded in 2013 and headquartered in San Carlos, California, that develops vaccines designed to prevent or treat some of the most common and deadly bacterial infectious diseases worldwide. The company's pipeline targets invasive pneumococcal disease (IPD), Group A Streptococcus, and Shigella—a set of pathogens aligned with the WHO's list of highest-priority antibiotic-resistant threats. Vaxcyte's portfolio is led by VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) currently in Phase 3 adult trials with FDA Breakthrough Therapy designation, followed by VAX-24 (24-valent PCV, Phase 2 infant study), VAX-A1 (Group A Strep, Phase 1), VAX-GI (Shigella, preclinical with NIH funding), and VAX-XL (third-generation PCV, preclinical).

All candidates are built on Vaxcyte's proprietary XpressCF cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, which enables site-specific, carrier-sparing conjugation that uses approximately half the protein of conventional vaccines while preserving T-cell epitopes. This architecture allows incremental serotypes to be added without compromising immunogenicity—VAX-31 is designed to cover 95%+ of IPD circulating in US adults aged 50+ and 12-40% more serotypes than current standard-of-care PCVs. Vaxcyte has scaled the platform through a GMP facility and is investing up to $1 billion in a new U.S. fill-finish manufacturing facility in North Carolina.

The company has no approved products or product revenue and operates a pre-commercial business model. Upon regulatory approval, Vaxcyte intends to generate revenue through direct sales of its vaccine products to healthcare provider networks, hospitals, public health systems, and government vaccination programs for both adult and pediatric populations. Primary customer segments include adults aged 50+ (PCV), infants and young children (PCV), and global populations at risk from Group A Strep and Shigella. The company held approximately $2.4 billion in cash at last reporting (providing runway through at least end of 2028) and has raised over $4.7 billion cumulatively through repeated public equity offerings since 2022.

Short descriptiontext

Vaxcyte is a clinical-stage vaccine company developing broad-spectrum pneumococcal conjugate vaccines (VAX-31, VAX-24) plus candidates for Group A Strep and Shigella, using its proprietary XpressCF cell-free protein synthesis platform. It targets adults 50+, infants, and global at-risk populations via healthcare providers and public health systems post-approval.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersSan Carlos, United States
HQ citystring
San Carlos
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pneumococcal conjugate vaccines, cell-free protein synthesis, infectious disease vaccines, carrier-sparing conjugation, bacterial vaccine pipeline
Industry2 codes
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Vaccines
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Vaccine Product Sales
TypeOne Time License
Description

Vaxcyte is a clinical-stage vaccine company with no current product revenue. The company is developing pneumococcal conjugate vaccines (VAX-31, VAX-24), a Group A Strep vaccine (VAX-A1), and a Shigella vaccine (VAX-GI). Upon regulatory approval, the company will generate revenue through sales of its vaccine products to healthcare providers, governments, and distribution partners.

ad-hoc-news.de
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Vaxcyte is a clinical-stage vaccine innovation company developing a portfolio of high-fidelity vaccines using its proprietary XpressCF cell-free protein synthesis platform. Its lead candidates are VAX-31 (31-valent) and VAX-24 (24-valent) pneumococcal conjugate vaccines designed to prevent invasive pneumococcal disease in adults and infants, with additional pipeline assets targeting Group A Streptococcus (VAX-A1) and Shigella (VAX-GI). The company is pre-commercial and has no approved products or product revenue, with its first launches planned following regulatory approval.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • VAX-31 High Dose met non-inferiority criteria for all 20 serotypes common with Prevnar 20 and superiority criteria for all 11 additional serotypes in Phase 1/2 trial of 1,015 healthy adults aged 50+
+4 more records
Product overview1 text field

Vaxcyte is a clinical-stage vaccine innovation company developing a portfolio of high-fidelity vaccines using its proprietary cell-free protein synthesis platform (XpressCF). The company's core PCV franchise includes VAX-31 (31-valent) and VAX-24 (24-valent) pneumococcal conjugate vaccines for the prevention of invasive pneumococcal disease. Beyond pneumococcal vaccines, the pipeline includes VAX-A1 (Group A Streptococcus vaccine in Phase 1), VAX-GI (Shigella vaccine in preclinical), and VAX-XL (third-generation PCV in preclinical). The technology platform enables site-specific, carrier-sparing conjugation for enhanced immunogenicity.

Product and service4 records
1VAX-31
Categorycore product
Description

31-valent pneumococcal conjugate vaccine (PCV) candidate for the prevention of invasive pneumococcal disease (IPD) and pneumonia, advancing through Phase 3 adult clinical program and Phase 2 infant clinical program. It is the broadest-spectrum PCV in clinical development, designed to provide protection against both currently circulating and historically prevalent serotypes.

2VAX-24
Categorycore product
Description

24-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in a Phase 2 infant study for the prevention of invasive pneumococcal disease. Designed to cover more serotypes than any infant PCV on-market today.

3VAX-A1
Categorycore product
Description

Novel investigational prophylactic vaccine candidate targeting Group A Streptococcus for the prevention of disease caused by Group A Strep in healthy adults. Currently in Phase 1 first-in-human clinical trial.

4VAX-GI
Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or Integration
Description

Sutro Biopharma has exclusively licensed its XpressCF® cell-free protein synthesis platform to Vaxcyte for vaccine development. This platform enables Vaxcyte to overcome limitations of traditional cell-based methods by separating cellular biochemical components into an extract that includes everything required for transcription, translation and energy production. Sutro has scaled the platform at its GMP facility, and Vaxcyte has also exercised options for XtractCF manufacturing rights totaling $75 million across 2023-2024. Blackstone Life Sciences has a revenue interest on Vaxcyte royalties as part of their partnership with Sutro.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Sells Prevnar 13/20, the dominant pneumococcal conjugate vaccines globally and direct comparator to Vaxcyte's VAX-31/VAX-24. Pfizer's established commercial, manufacturing, and ACIP relationships make it the most consequential incumbent competitor in Vaxcyte's lead indication.

TypeBroad incumbent
Description

Markets Vaxneuvance (PCV15) and V116, a 21-valent PCV, directly competing with Vaxcyte's pneumococcal franchise. Operates one of the largest vaccine commercial organizations globally.

TypeBroad incumbent
Description

mRNA vaccine platform company with an infectious disease pipeline that overlaps Vaxcyte's strategic ambition of building a broad-spectrum vaccine franchise. Shares the public-market vaccine-innovator narrative and competitor-for-capital dynamic.

TypeBroad incumbent
Description

Operates Sanofi Pasteur, a global vaccine business with established conjugate vaccine capabilities and a pediatric/Adult vaccine portfolio. A potential partner or acquirer for Vaxcyte given complementary technology and global commercial reach.

TypeBroad incumbent
Description

Major vaccine manufacturer with a broad infectious disease portfolio. Competes for institutional buyers and public health customers that Vaxcyte targets with its PCV franchise.

TypeOthers
Description

Licensor of the XpressCF cell-free protein synthesis platform that underpins Vaxcyte's vaccine pipeline. Platform partner and economic stakeholder via royalties and Blackstone revenue interest; also develops ADCs using the same underlying platform.

TypeEmerging player
Description

Clinical-to-commercial-stage vaccine company using a nanoparticle platform for infectious disease targets. Similar late-stage clinical/biotech profile and infectious-disease strategic focus to Vaxcyte.

TypeEmerging player
Description

mRNA-based vaccine developer with an expanding infectious disease pipeline beyond COVID-19. Competes for talent, capital, and partner attention in the next-generation vaccine space.

TypeEmerging player
Description

Clinical-stage vaccine developer using a VLP platform for infectious disease targets including RSV and hMPV. Comparable profile as a small-cap, platform-based infectious disease vaccine company.

TypeEmerging player
Description

Commercial-stage vaccine company with CpG 1018 adjuvant used in HEPLISAV-B and other infectious disease vaccine programs. Comparable as a smaller, focused vaccine platform company.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds15 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vaxcyte

Vaccinesvaxcyte.com

Vaxcyte is a clinical-stage vaccine company developing broad-spectrum pneumococcal conjugate vaccines (VAX-31, VAX-24) plus candidates for Group A Strep and Shigella, using its proprietary XpressCF cell-free protein synthesis platform. It targets adults 50+, infants, and global at-risk populations via healthcare providers and public health systems post-approval.

What Vaxcyte does

Vaxcyte, Inc. (NASDAQ: PCVX) is a clinical-stage vaccine innovation company founded in 2013 and headquartered in San Carlos, California, that develops vaccines designed to prevent or treat some of the most common and deadly bacterial infectious diseases worldwide. The company's pipeline targets invasive pneumococcal disease (IPD), Group A Streptococcus, and Shigella—a set of pathogens aligned with the WHO's list of highest-priority antibiotic-resistant threats. Vaxcyte's portfolio is led by VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) currently in Phase 3 adult trials with FDA Breakthrough Therapy designation, followed by VAX-24 (24-valent PCV, Phase 2 infant study), VAX-A1 (Group A Strep, Phase 1), VAX-GI (Shigella, preclinical with NIH funding), and VAX-XL (third-generation PCV, preclinical).

All candidates are built on Vaxcyte's proprietary XpressCF cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, which enables site-specific, carrier-sparing conjugation that uses approximately half the protein of conventional vaccines while preserving T-cell epitopes. This architecture allows incremental serotypes to be added without compromising immunogenicity—VAX-31 is designed to cover 95%+ of IPD circulating in US adults aged 50+ and 12-40% more serotypes than current standard-of-care PCVs. Vaxcyte has scaled the platform through a GMP facility and is investing up to $1 billion in a new U.S. fill-finish manufacturing facility in North Carolina.

The company has no approved products or product revenue and operates a pre-commercial business model. Upon regulatory approval, Vaxcyte intends to generate revenue through direct sales of its vaccine products to healthcare provider networks, hospitals, public health systems, and government vaccination programs for both adult and pediatric populations. Primary customer segments include adults aged 50+ (PCV), infants and young children (PCV), and global populations at risk from Group A Strep and Shigella. The company held approximately $2.4 billion in cash at last reporting (providing runway through at least end of 2028) and has raised over $4.7 billion cumulatively through repeated public equity offerings since 2022.

Vaxcyte firmographics

Firmographics
Name
Vaxcyte
Legal name
Vaxcyte, Inc.
Website
https://vaxcyte.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Vaxcyte is a clinical-stage vaccine company developing broad-spectrum pneumococcal conjugate vaccines (VAX-31, VAX-24) plus candidates for Group A Strep and Shigella, using its proprietary XpressCF cell-free protein synthesis platform. It targets adults 50+, infants, and global at-risk populations via healthcare providers and public health systems post-approval.
Ownership category
akta.pro rank

Vaxcyte industry classification

Industry
Product category
Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Pneumococcal conjugate vaccines
  • Cell-free protein synthesis
  • Infectious disease vaccines
  • Carrier-sparing conjugation
  • Bacterial vaccine pipeline

Where Vaxcyte is headquartered

Location

Headquarters

HQ city
San Carlos
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Vaxcyte business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

  1. Vaccine Product Sales: Vaxcyte is a clinical-stage vaccine company with no current product revenue. The company is developing pneumococcal conjugate vaccines (VAX-31, VAX-24), a Group A Strep vaccine (VAX-A1), and a Shigella vaccine (VAX-GI). Upon regulatory approval, the company will generate revenue through sales of its vaccine products to healthcare providers, governments, and distribution partners.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Vaxcyte product offering

Product offering

Core offering

Vaxcyte is a clinical-stage vaccine innovation company developing a portfolio of high-fidelity vaccines using its proprietary XpressCF cell-free protein synthesis platform. Its lead candidates are VAX-31 (31-valent) and VAX-24 (24-valent) pneumococcal conjugate vaccines designed to prevent invasive pneumococcal disease in adults and infants, with additional pipeline assets targeting Group A Streptococcus (VAX-A1) and Shigella (VAX-GI). The company is pre-commercial and has no approved products or product revenue, with its first launches planned following regulatory approval.

Product overview

Vaxcyte is a clinical-stage vaccine innovation company developing a portfolio of high-fidelity vaccines using its proprietary cell-free protein synthesis platform (XpressCF). The company's core PCV franchise includes VAX-31 (31-valent) and VAX-24 (24-valent) pneumococcal conjugate vaccines for the prevention of invasive pneumococcal disease. Beyond pneumococcal vaccines, the pipeline includes VAX-A1 (Group A Streptococcus vaccine in Phase 1), VAX-GI (Shigella vaccine in preclinical), and VAX-XL (third-generation PCV in preclinical). The technology platform enables site-specific, carrier-sparing conjugation for enhanced immunogenicity.

Differentiator

Problem solved

Functional benefit

Products and services

  • VAX-31 31-valent pneumococcal conjugate vaccine (PCV) candidate for the prevention of invasive pneumococcal disease (IPD) and pneumonia, advancing through Phase 3 adult clinical program and Phase 2 infant clinical program. It is the broadest-spectrum PCV in clinical development, designed to provide protection against both currently circulating and historically prevalent serotypes.
  • VAX-24 24-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in a Phase 2 infant study for the prevention of invasive pneumococcal disease. Designed to cover more serotypes than any infant PCV on-market today.
  • VAX-A1 Novel investigational prophylactic vaccine candidate targeting Group A Streptococcus for the prevention of disease caused by Group A Strep in healthy adults. Currently in Phase 1 first-in-human clinical trial.
  • VAX-GI

Quantifiable outcome

  • VAX-31 High Dose met non-inferiority criteria for all 20 serotypes common with Prevnar 20 and superiority criteria for all 11 additional serotypes in Phase 1/2 trial of 1,015 healthy adults aged 50+
  • +4 more outcomes

Companies that use Vaxcyte

Customer profile

Segments4 records

Ideal customer profiles2 records

Vaxcyte technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Vaxcyte partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Sutro BiopharmacoreTechnology or IntegrationSutro Biopharma has exclusively licensed its XpressCF® cell-free protein synthesis platform to Vaxcyte for vaccine development. This platform enables Vaxcyte to overcome limitations of traditional cell-based methods by separating cellular biochemical components into an extract that includes everything required for transcription, translation and energy production. Sutro has scaled the platform at its GMP facility, and Vaxcyte has also exercised options for XtractCF manufacturing rights totaling $75 million across 2023-2024. Blackstone Life Sciences has a revenue interest on Vaxcyte royalties as part of their partnership with Sutro.

Scale indicators14 records

Recent moves6 records

Expansion highlights5 records

Vaxcyte competitors and assessment

Company assessment

Broad incumbents

  • Pfizer: Sells Prevnar 13/20, the dominant pneumococcal conjugate vaccines globally and direct comparator to Vaxcyte's VAX-31/VAX-24. Pfizer's established commercial, manufacturing, and ACIP relationships make it the most consequential incumbent competitor in Vaxcyte's lead indication.
  • Merck: Markets Vaxneuvance (PCV15) and V116, a 21-valent PCV, directly competing with Vaxcyte's pneumococcal franchise. Operates one of the largest vaccine commercial organizations globally.
  • Moderna: mRNA vaccine platform company with an infectious disease pipeline that overlaps Vaxcyte's strategic ambition of building a broad-spectrum vaccine franchise. Shares the public-market vaccine-innovator narrative and competitor-for-capital dynamic.
  • Sanofi: Operates Sanofi Pasteur, a global vaccine business with established conjugate vaccine capabilities and a pediatric/Adult vaccine portfolio. A potential partner or acquirer for Vaxcyte given complementary technology and global commercial reach.
  • GSK: Major vaccine manufacturer with a broad infectious disease portfolio. Competes for institutional buyers and public health customers that Vaxcyte targets with its PCV franchise.

Others

  • Sutro Biopharma: Licensor of the XpressCF cell-free protein synthesis platform that underpins Vaxcyte's vaccine pipeline. Platform partner and economic stakeholder via royalties and Blackstone revenue interest; also develops ADCs using the same underlying platform.

Emerging players

  • Novavax: Clinical-to-commercial-stage vaccine company using a nanoparticle platform for infectious disease targets. Similar late-stage clinical/biotech profile and infectious-disease strategic focus to Vaxcyte.
  • BioNTech: mRNA-based vaccine developer with an expanding infectious disease pipeline beyond COVID-19. Competes for talent, capital, and partner attention in the next-generation vaccine space.
  • Icosavax: Clinical-stage vaccine developer using a VLP platform for infectious disease targets including RSV and hMPV. Comparable profile as a small-cap, platform-based infectious disease vaccine company.
  • Dynavax Technologies: Commercial-stage vaccine company with CpG 1018 adjuvant used in HEPLISAV-B and other infectious disease vaccine programs. Comparable as a smaller, focused vaccine platform company.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Vaxcyte social profiles

Digital presence

Vaxcyte financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vaxcyte leadership team

Management profile

Number of profiles

Profiles11 records

Vaxcyte funding detail

Funding detail

Funding overview

Funding rounds15 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vaxcyte M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vaxcyte

What does Vaxcyte do?

Vaxcyte is a clinical-stage vaccine innovation company developing a portfolio of high-fidelity vaccines using its proprietary XpressCF cell-free protein synthesis platform. Its lead candidates are VAX-31 (31-valent) and VAX-24 (24-valent) pneumococcal conjugate vaccines designed to prevent invasive pneumococcal disease in adults and infants, with additional pipeline assets targeting Group A Streptococcus (VAX-A1) and Shigella (VAX-GI). The company is pre-commercial and has no approved products or product revenue, with its first launches planned following regulatory approval.

Is Vaxcyte a public or private company?

Vaxcyte is a public company. It is classified as public and is currently operating.

When was Vaxcyte founded?

Vaxcyte was founded in 2013. It employs 501 to 1,000 people.

Where is Vaxcyte based?

Vaxcyte is headquartered in San Carlos, United States, in the North America region.

How does Vaxcyte make money?

One revenue line is on record: vaccine Product Sales.

Who are Vaxcyte's main competitors?

Broad incumbents on record are Pfizer, Merck, Moderna, Sanofi and GSK. Sutro Biopharma is listed as an others. Emerging players are Novavax, BioNTech, Icosavax and Dynavax Technologies.

Does Vaxcyte have an API?

No public API is recorded for Vaxcyte.

What industry is Vaxcyte in?

Vaxcyte's product category is Vaccines. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAAAEAK, Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StIs Vaxcyte (PCVX) Undervalued On Wider Losses And A Softer Share Price?Vaxcyte reported wider net losses for Q3 and the first nine months of 2026, with its stock down 6.2% over 30 days. Analysts see a fair value of $117.30 versus the current $63.37, citing late-stage vaccine programs and a US$3.0b cash reserve.Simply Wall StVaxcyte Stock After Wider Q3 Losses Has The Bull Case Changed?Vaxcyte reported a Q3 2026 net loss of $297.06 million and a nine-month loss of $901.99 million, with a cash balance of about $3.0 billion. The widening losses reflect heavy R&D and manufacturing spend in its pre-revenue phase, with near-term catalysts remaining clinical and regulatory progress for VAX 31.Investing.comVaxcyte at guggenheim healthcare conference: strong vaccine data, long roadVaxcyte presented strong Phase III data for its 31-valent pneumococcal vaccine VAX-31, including 11-for-11 primary endpoints. The company targets a Biologics License Application submission in the first half of 2028, with about $3.4 billion in cash. It also advanced its infant VAX-31 program and Group A Strep vaccine VAX-A1.Simply Wall St3 Growth Stocks With Earnings Growth Over 32%Three growth stocks—Vaxcyte, Penguin Solutions, and Palantir—are highlighted for earnings growth exceeding 32%. Vaxcyte has a $10.1B market cap, Penguin Solutions $2.5B, and Palantir $386.4B. The article notes AI-driven demand and vaccine programs as key drivers.Defense WorldCandriam S.C.A. Acquires 239,206 Shares of Vaxcyte, Inc. $PCVXCandriam S.C.A. increased its Vaxcyte stake by 115% in Q3, holding 447,260 shares worth $25.5 million. Insiders sold 50,692 shares in three months, and analysts rate the stock a Moderate Buy with a $110.50 average price target.American Banking and Market NewsVaxcyte, Inc. $PCVX Holdings Raised by Candriam S.C.A.Candriam S.C.A. increased its stake in Vaxcyte by 115% in Q3, holding 447,260 shares worth $25.5 million. Analysts have an average price target of $110.50, with most rating the stock a buy. The company reported a loss of $1.99 per share for the quarter.Simply Wall StVaxcyte Stock Gets A Lift From Strong Vaccine Trial ResultsVaxcyte reported a Q3 net loss of $297.06 million and a basic loss per share of $1.99. Its VAX-31 pneumococcal vaccine candidate met all primary endpoints in adults with a safety profile similar to existing vaccines. The company projects $748.4 million revenue and $119.1 million earnings by 2029.Seeking AlphaVaxcyte GAAP EPS of -$1.99 beats by $0.15 (NASDAQ:PCVX)Vaxcyte reported Q3 GAAP EPS of -$1.99, beating by $0.15. Cash, cash equivalents, and investments totaled $2,264.4 million as of September 30, 2026, down from $2,442.6 million a year earlier. The company excluded approximately $1.1 billion in net proceeds from October 2026 offerings.Investing.comPfizer earnings on deck: Prevnar pressures test growth storyPfizer reports Q3 earnings Tuesday, with analysts expecting EPS of 73 cents and revenue of $15.91 billion, down 15.8% year-over-year. The Prevnar vaccine franchise faces competition from Vaxcyte's VAX-31, and investors will watch COVID franchise guidance and pipeline updates.moneyweekukThree top-class smaller biotechnology companies to invest inGeoffrey Hsu highlights three smaller biotech firms: United Therapeutics, Vaxcyte, and Palvella Therapeutics. United Therapeutics expects a US regulatory decision on its IPF drug Tyvaso in spring 2027, while Vaxcyte reported positive Phase III results for its pneumococcal vaccine. Palvella is developing a rapamycin gel for lymphatic malformations, with a potential 2027 launch.